How PI3 Kinase Controls Cell Growth, Metabolism, and Cancer

PI3 kinase, usually written PI3K, is a family of enzymes that sit at a critical crossroads inside your cells, translating signals from hormones, growth factors, and immune molecules into instructions for growth, survival, movement, and metabolism. When PI3K works normally, it keeps tissues growing and renewing on schedule. When it malfunctions, often through a single mutation in the gene encoding it, the result can be uncontrolled cell growth and cancer. That dual nature has made PI3K one of the most intensely studied and most drugged targets in modern oncology, but its influence extends well beyond tumors into immunity, brain function, aging, and metabolic disease.

How PI3K Was Discovered

The enzyme’s story starts with an unlikely source: a mouse virus. Researchers studying polyoma middle T antigen, a protein made by a DNA tumor virus that transforms normal cells into cancerous ones, noticed that the viral protein assembled a complex of signaling molecules on the inner face of the cell membrane. Among those molecules was a previously unrecognized enzyme that added a phosphate group to a specific membrane lipid. That enzyme turned out to be PI3K. The discovery, alongside the identification of several other signaling proteins recruited by the same viral protein, opened up an entirely new area of mammalian growth-control biology.¹ From that starting point, decades of work have mapped PI3K into a large family of related enzymes grouped into three classes, each with different jobs, different tissue distributions, and different disease connections.

What PI3K Does Inside a Cell

The basic job of class I PI3K, the most studied group, is to convert one membrane lipid into another. When a growth factor or hormone docks onto a receptor on the cell surface, PI3K is recruited to the inner membrane and generates a lipid called PIP3. That lipid acts as a landing pad, pulling specific proteins to the membrane so they can be switched on. The most important protein recruited this way is a kinase commonly known as Akt. Once Akt reaches the membrane, it gets activated by two other kinases, PDK1 and mTORC2, and then goes on to phosphorylate dozens of downstream targets that promote cell survival, protein production, and cell division.²

Class I PI3Ks come in two subgroups. Class IA enzymes pair a catalytic subunit (p110α, p110β, or p110δ) with a regulatory subunit from the p85 family. The regulatory subunit does triple duty: it stabilizes the catalytic subunit, keeps it inactive until the right signal arrives, and physically links the enzyme to activated receptors at the membrane.³ Class IB consists of a single catalytic subunit, p110γ, paired with its own regulatory partners. The different catalytic isoforms are not interchangeable; they are expressed in different tissues and wired into different signaling contexts, which matters enormously for drug development.

PTEN, the Natural Brake

Every accelerator needs a brake, and for PI3K signaling that brake is PTEN. PTEN is a phosphatase, meaning it removes the phosphate group that PI3K adds to membrane lipids. By stripping PIP3 back down, PTEN shuts off Akt and all the downstream signals that promote growth. PTEN is one of the most commonly lost or mutated tumor suppressors in human cancer, and when it disappears, PI3K signaling runs unchecked even without a mutation in PI3K itself.⁴ This means that cancers driven by PI3K pathway overactivity can arrive at that state through at least two different genetic routes: gain-of-function mutations in PI3K, or loss-of-function mutations in PTEN. Both converge on the same outcome of too much PIP3 and too much Akt activity.

PI3K in the Immune System

Two of the class I catalytic isoforms, p110δ and p110γ, are expressed at high levels in white blood cells, and their roles there are so specialized that they have become drug targets in their own right. PI3Kγ is particularly important for the recruitment and activation of innate immune cells at sites of inflammation, helping neutrophils and macrophages respond to chemokine signals. PI3Kδ, meanwhile, plays a central role in the development and function of B cells and T cells, the adaptive arm of immunity.⁵ These two isoforms have distinct, non-overlapping functions: PI3Kδ governs lymphocyte signaling while PI3Kγ drives myeloid cell responses.⁶

Natural killer cells, which patrol the body for virus-infected and cancerous cells, also rely on both isoforms for migration. Studies using gene-targeted mice showed that both p110γ and p110δ were essential for NK cell chemotaxis, but p110δ had the more far-reaching role, controlling NK cell distribution across tissues and their ability to infiltrate tumors.⁷ The heavy reliance of immune cells on these isoforms explains both the therapeutic opportunity and the side-effect risks of targeting them with drugs.

PI3K and Metabolism

PI3K is not just about growth and immunity. It is also a critical node in insulin signaling. When insulin binds its receptor, class IA PI3K is one of the first enzymes activated, and the downstream Akt activity it triggers is what tells cells to take up glucose, store fat, and synthesize glycogen. When this pathway is disrupted in muscle, fat, liver, brain, or pancreas, the result is insulin resistance, which can spiral into obesity and type 2 diabetes.⁸ Insulin resistance, in turn, further damages PI3K/Akt signaling, creating a vicious cycle. This metabolic connection has major implications for cancer therapy, as we will see when discussing drug side effects.

Cancer Mutations in PIK3CA

The gene encoding the p110α catalytic subunit, called PIK3CA, is one of the most frequently mutated oncogenes across all human cancers. Mutations cluster in two hotspot regions of the protein: the helical domain and the kinase domain. Both types of mutation produce a gain of enzymatic function, meaning the enzyme becomes overactive, but they achieve this through different molecular mechanisms.⁹ The single most common mutation is H1047R, a substitution in the kinase domain that leads to enzymatic overactivation and drives cell proliferation and survival.¹⁰

These mutations show up in breast, colon, endometrial, ovarian, and many other solid tumors. Because the mutations are so common and produce a clearly druggable overactive enzyme, they became an obvious target for drug developers. But there is a catch: the normal, unmutated version of p110α is essential for insulin signaling throughout the body. Any drug that blocks the mutant enzyme also tends to block the normal one, causing metabolic side effects.

PI3K Pathway Activation in the Tumor Microenvironment

PI3K’s role in cancer is not limited to mutations inside the tumor cells themselves. The pathway also shapes the environment around a tumor. Research has shown that tumor-derived signals can activate the PI3K/Akt pathway in nearby immune cells, particularly macrophages, pushing them toward a pro-tumor state known as M2 polarization. M2 macrophages then secrete factors that promote new blood vessel formation, helping the tumor grow and spread. In esophageal squamous cell carcinoma, for instance, tumor-derived exosomes were found to suppress PTEN in macrophages, activating PI3K/Akt signaling and driving both M2 polarization and angiogenesis through the release of VEGFA and MMP9.¹¹ Similar findings have appeared in lung cancer, where blocking PI3K/Akt in macrophages suppressed their tumor-promoting behavior and reduced angiogenesis.¹²

PI3K Inhibitor Drugs in Solid Tumors

The first PI3K-targeting drug to make a major impact in solid tumors was alpelisib, an inhibitor selective for the p110α isoform. In the pivotal trial for hormone-receptor-positive, HER2-negative advanced breast cancer with PIK3CA mutations, alpelisib combined with the hormone therapy fulvestrant roughly doubled progression-free survival compared to fulvestrant alone: about 11 months versus about 5.7 months.¹³ The benefit was specific to the patients whose tumors carried PIK3CA mutations; in patients without those mutations, the drug added little. An earlier first-in-human study had already shown that alpelisib was active across a range of PIK3CA-altered solid tumors, providing the rationale for combining it with other agents.¹⁴

PI3K Inhibitors in Blood Cancers

In hematologic malignancies, the relevant PI3K isoforms are δ and γ rather than α, reflecting the immune-cell-heavy biology of these cancers. Idelalisib, the first-in-class PI3Kδ inhibitor, was approved in 2014 for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma. In CLL, PI3Kδ is hyperactivated and plays a pivotal role in the B-cell receptor pathway, which is a key driver of these malignancies.¹⁵ Duvelisib, which targets both p110γ and p110δ, followed with a similar efficacy and safety profile. Umbralisib, a dual p110δ and CK-1ε inhibitor, was also studied as a safer option, though its regulatory history has been bumpy.¹⁶

Side Effects and the Hyperglycemia Problem

The biggest clinical headache with PI3Kα inhibitors is hyperglycemia, high blood sugar. Because PI3Kα is the same enzyme that transmits insulin’s signals, blocking it to fight cancer also impairs glucose uptake. This is an on-target effect, not an off-target surprise; the drug is doing exactly what it was designed to do, and high blood sugar is the predictable metabolic consequence.¹⁷ Managing it typically requires glucose-lowering medications and dietary changes.¹⁸

The immune-selective inhibitors (idelalisib, duvelisib) have a different set of problems. Because PI3Kδ plays such a central role in regulatory T cells, blocking it can unleash autoimmune-like inflammation. In one study of idelalisib given as a front-line CLL treatment, roughly four out of five patients developed liver enzyme elevations, and over half experienced severe hepatotoxicity. Liver biopsies showed lymphocytic infiltrates consistent with an immune-mediated attack, and patients experiencing the toxicity had elevated inflammatory cytokines and reduced regulatory T cells. Immunosuppressive treatment, typically steroids, resolved the episodes.¹⁹

Why Tumors Resist PI3K Inhibitors

Even when PI3K inhibitors initially shrink a tumor, resistance often develops. One well-characterized escape route involves feedback loops. In cells that overexpress certain receptor tyrosine kinases, blocking PI3K shuts down Akt, which normally keeps expression of those receptors in check. Once that suppression is lifted, the receptors bounce back, get re-phosphorylated, and re-activate PI3K or parallel pathways, effectively routing around the drug.²⁰ This feedback reactivation of receptor signaling is one of the main reasons PI3K inhibitors work better in combination with other drugs than as single agents. It also explains why the drug development field has moved toward designing inhibitors that are more selective or that target the mutant enzyme while leaving the normal version alone.

Next-Generation Mutant-Selective Inhibitors

The recognition that blocking normal PI3Kα causes metabolic havoc while blocking the mutant enzyme kills tumors has spurred a new generation of drugs designed to discriminate between the two. STX-478, for example, is an allosteric inhibitor, meaning it binds outside the enzyme’s active site and preferentially targets mutant p110α. Early clinical data showed that in heavily pre-treated breast cancer patients with PIK3CA mutations, about a quarter with measurable disease had tumor shrinkage, and the drug was well tolerated with infrequent metabolic side effects even in patients with diabetes or prior intolerance to older PI3K drugs.²¹ Responses were seen across both kinase-domain and helical-domain mutations, suggesting the allosteric approach can cover the major hotspots. This kind of structural selectivity was informed by cryo-electron microscopy work that mapped out the different shapes PI3Kα adopts when it is inactive, inhibited, and activated, revealing druggable pockets that differ between the mutant and normal forms.²²

Diet and Drug Efficacy

One of the more surprising findings in PI3K inhibitor research is that diet can significantly affect how well the drugs work. The hyperglycemia caused by PI3Kα inhibition triggers a compensatory surge in insulin secretion. That extra insulin can reactivate the very PI3K pathway the drug is trying to shut down in tumor cells, undermining the treatment. Preclinical work published in Nature showed that preventing this insulin feedback, whether through a ketogenic diet, caloric restriction, or insulin-lowering medications, dramatically improved the efficacy-to-toxicity ratio of PI3K inhibitors.²³ Clinical management guidelines now recommend combining low-carbohydrate diets with glucose-lowering medications for patients on these drugs.²⁴ It is a rare case in oncology where what a patient eats can directly modulate how well a targeted therapy performs.

PI3K in the Brain

Outside of cancer and metabolism, PI3K has quietly accumulated an impressive research portfolio in neuroscience. The PI3K/Akt pathway contributes to synaptic plasticity, the ability of connections between neurons to strengthen or weaken, which underlies learning and memory. Rat studies showed that blocking PI3K interfered with memory consolidation, and the mechanism appeared to involve both cell-survival signaling and protein synthesis through the mTOR pathway.²⁵

More recent work has teased apart which isoforms do what in the brain. The p110α isoform turns out to be the main supporter of dendritic and postsynaptic structures, essentially the receiving end of neuronal connections. The p110β isoform, by contrast, controls neurotransmitter release at the presynaptic terminal and a specific form of synaptic weakening. Both isoforms jointly contribute to the type of synaptic strengthening that is most closely associated with learning. Mice lacking one isoform or the other show distinct behavioral impairments in learning, memory, and social behavior.²⁶

Autophagy and Cellular Housekeeping

Class III PI3K, known as Vps34, operates in a completely different arena from the growth-signaling class I enzymes. Vps34 generates a lipid called PI3P on internal membranes, which serves as a signal for vesicle trafficking and autophagy, the process by which cells break down and recycle their own damaged components. Genetic deletion of Vps34 in mice blocks both endocytic degradation and starvation-induced autophagy, and animals lacking the enzyme in liver or heart tissue develop severe organ dysfunction.²⁷ Class II PI3Ks also contribute to autophagy by providing an additional source of PI3P; when both class II and class III enzymes are knocked out simultaneously, the defect in autophagy is worse than losing either one alone.²⁸

Scaffolding Roles Beyond Enzyme Activity

One of the more counterintuitive discoveries about PI3K is that some family members have important functions that do not require their enzymatic activity at all. Studies comparing knockout mice (which lack the protein entirely) with kinase-dead knock-in mice (which have the protein but it cannot phosphorylate anything) revealed that p110γ and p110β can act as scaffold or adaptor proteins, organizing signaling complexes independent of their ability to make PIP3.²⁹ Similarly, the p85 regulatory subunits have been found to perform critical adaptor functions when they are not bound to a catalytic subunit. Free p85 influences glucose homeostasis, cellular stress responses, receptor trafficking, and cell migration, all independently of PI3K catalytic activity.³⁰ These findings complicate the simple model of PI3K as just a lipid kinase and suggest that drugs blocking only the enzyme’s catalytic activity may miss part of the picture.

PI3K and Aging

The connection between PI3K and lifespan may be the most dramatic illustration of how deeply this enzyme is wired into fundamental biology. In the nematode worm, genetic disruption of insulin-like signaling, which operates through PI3K, extends lifespan by 1.5 to 3 times. The effect is smaller in fruit flies and mice, but the direction is consistent across species.³¹ The long-lived worms also show enhanced resistance to environmental stress. Whether any of this translates to human aging interventions remains speculative, but the finding underscores PI3K’s position at the intersection of growth, metabolism, and organismal survival. Turning down the growth signal appears, in simple organisms at least, to trade reproductive vigor for durability.